Evaluation and Treatment of Hypertension

Size: px
Start display at page:

Download "Evaluation and Treatment of Hypertension"

Transcription

1 Practical Pearls for Clinical Dilemmas in Primary Care Evaluation and Treatment of Hypertension A 58 yo man is diagnosed with hypertension. His BP s are 160/96, 160/100, and 158/96 on 3 outside readings. He has been on a low sodium diet and he is not obese. PMH- hyperlipidemia, GERD and gout. What would be the most appropriate treatment? A) Low salt diet and exercise B) Hydrochlorathiazide C) Doxazosin D) ACE inhibitor When Thiazides Are Not A Good Choice History of Gout Creatinine > 1.6 Lithium use Diuretic Choice Strongly consider chlorthalidone Long acting, great data Major drawback has been hypokalemia Are Beta blockers efficacious antihypertensive therapy in the elderly? Meta analysis of 10 randomized trials (at least 1 year in duration) 16, 164 elderly ( 60 yr) patients included 2/3 of patients on diuretics controlled on monotherapy, < 1/3 patients on b-blockers well controlled Diuretics effective in CVA, CAD, cardiovascular mortality and all cause mortality. B-blockers only decreased cerebrovascular events. JAMA 1998; 279:

2 A 60 yo man presents for follow-up of hypertension. He has been taking medication (Lisinopril) for the past 3 months. His most recent outside blood pressure readings are 156/94, 150/96, 158/92. PMH: Type 2 DM, GERD, depression. Meds: Lisinopril 20mg qd, Rabeprazole 20mg qd, Sertraline 50 mg qd, Glyburide 10 mg qd. What do you recommend? A) No changes in therapy B) Increase Lisinopril to 20 mg BID C) Add Hydrochlorathiazide 12.5 mg qd D) Add Amlodipine (Norvasc) 5mg qd E) Add Clonidine.1mg BID Outcomes with Different Combination Regimens for Hypertension (ACCOMPLISH) 6946 patients with diabetes and HTN randomized to benazapril and HCTZ or Benazapril and amlodipine,in addition 4,559 patients without DM were also studied. BP lowering same with both combinations, reduced CV events in patients on B +A (HR.79, CI , p <.003) J AM Coll Cardiol 2010;56 (1): Combination Therapy Combining a thiazide with B blocker or an ACE has a synergistic effect, controlling BP in up to 85% Combination of ACEI with amlodipine may be superior to ACEI + diuretic in patients with diabetes (less CV events) Low doses of thiazide can be very effective in combination with ACE inhibitors (12.5 mg of thiazide) Thiazide ACE combination can be further enhanced by moderate dietary salt restriction A 58 yo woman is seen for treatment of hypertension. She has not ever had good control of her hypertension since treatment was started 2 years ago. She has been taking her medications faithfully. Meds: Felodipine (Plendil), Atenolol, Clonidine, and Losartan (Cozaar). On exam her BP is 200/106 P-55.Labs- BUN 30, Cr 2.0, Na 137, K 4.0. ECG- LVH What would you recommend? A) Increase felodipine from 10mg a day to 10mg BID B) Increase losartan from 50mg BID to 100mg BID C) Add hydrochlorathiazide 12.5 mg qd D) Add hydrochlorathiazide 25 mg qd E) Add furosemide 40 mg BID Refractory Hypertension Occurs in 5% of hypertensive patients Always carefully evaluate for medication adherence. Worse with increasing obesity Think of secondary causes Sleep apnea Ingestion of substances that interfere with treatment (especially NSAIDS) Treatment of Refractory Hypertension Most have too much volume. Furosemide extremely useful, especially if renal insufficiency present Consider spironolactone Simplify regimens if possible to improve adherence 2 2

3 AHA Recommendations For Treatment of Hypertension Indication BP goal Initial therapy B Blocker Low risk <140/90 ACE/CCB/Thi No High risk <130/80 ACE/CCB/Thi No With CAD <130/80 BB and ACE Yes CHF < 120/80 BB/ACE/Aldo Yes Diuretics Hypertension Pearls Losartan can lower uric acid A low potassium level in a patient with untreated hypertension suggests a hyperaldosterone state ( hyperaldosteronism due to adrenal hyperplasia > renal artery stenosis) Treat renal artery stenosis medically, not surgically or with stents How Can You Tell What Kind Of Headache It Is? A 29 yo woman is evaluated for headaches. She reports having headaches about twice a month. She feels pain behind her right eye and frequently pain on her forehead. Her headaches often get better with 550 mg of Naprosyn. She has never had visual problems or nausea with her headaches. The headaches are worse with exercise. About once a month the headache is bad enough to force her to leave work early. What is the Most Likely Type of Headache? A)Migraine B)Cluster C)Muscle tension D)Nitrate headache Clinical Features of Tension Type Headache Mild Headache Often described as tightness, vice like Neck to forehead can be involved Often helped by NSAIDS Worse during times of stress Not disabling 3 3

4 Clinical Features of Migraine Headaches Family history common Pulsating quality Worse with activity Mild to Severe in intensity Can be disabling History of motion sickness common Nausea, photophobia, phonophobia may occur Diagnosing Migraine POUNDing Pneumonic Pulsating Duration 4-72 hours Unilateral Nausea Disabling If 4 criteria met LR is 24 for migraine If 3 met LR 3.5 If 2 or fewer LR.41 JAMA 2006: 296: Frequency of Headache Types Tension Type Most common Migraine - Common Cluster - Rare Role of Metoclopramide Good efficacy when combined with NSAID. Equivalent to sumatriptan oral if patient has nausea. My boost effect of oral triptan or other oral migraine treatments Metoclopramide vs Hydromorphone Retrospective cohort study to evaluate metoclopramide vs hydromorphone for initial ED treatment of migraine 200 patients, 51 received IV or IM hydromorphone, 95 received IV metoclopramide and 54 received a different medication. Using a 1-10 pain scale, mean pain scale reductions were 2.3 for hydromorphone, 3.7 for metoclopramide and 2,8 for all other meds (p<.001). Less rescue meds and faster ED discharge with metoclopramide J Pain 2008;9 (1): Oral treatment protocol for moderate to severe HA NSAID + motility drug (Metoclopramide) no relief Oral triptan no relief Oral narcotic no relief ER/office visit for IV therapy 4 4

5 Vascular Headache Prophylaxis Effective B Blocker (propranolol, metoprolol) Tricyclic antidepressant (amitriptyline) Riboflavin Valproate/Topiramate> Gabapentin Migraine Prophylaxis Options for the patients who fail standard prophylaxis Leukotriene inhibitors ACE inhibitors (Lisinopril mg) Calcium channel blockers (Candesartan 16 mg) Less Effective Calcium channel blocker Memantine for Prevention of Refractory Migraine Patients with refractory migraine studied (8-14 headache days per month or failure of 2 previous preventive treatments in patients with transformed migraine) received mg of memantine daily for 3 months 28 patients in this open labeled study. HA frequency reduced from 21.8 days to 16.1 days (p<.01), Days with severe pain reduced from 7.8 to 3.2 (p<.01). Side effects in 37.5 %, with 5.5% drop out due to side effects. Headache 2008;48 (9): Prophylaxis of migraine headaches Riboflavin B-blocker No response x 3 months No response x 3 months Add TCA No response x 3 months Valproate/topir>gaba Topiramate And Acidosis Topiramate acts as a carbonic anhydrase inhibitor Metabolic non anion gap hyperchloremic acidosis can occur Average drop in bicarbonate is 4, but can be severe, especially in the setting of surgery Lipid Treatment 5 5

6 A 36 yo man comes to clinic for an annual evaluation. He does not smoke and has no history of diabetes. He exercises for 45 minutes each day. His father had an MI at age 75 last year. His exam is normal (BP 120/70). Lipid testing shows TC 170, Tri 150, HDL 45, LDL 120 HSCRP 2.1. What would you recommend for him? A) Niacin B) Fenofibrate C) Rosuvastatin D) No treatment Rosuvastatin To Prevent Vascular Events With High CRP 17,802 men and women (men >50, women > 60) with LDL less than 130 and HSCRP >2 randomized to Rosuvastatin 20 mg or placebo Primary end point (MI/Stroke/Unstable angina/revasc/death from CV).77/100 person years treatment vs 1.36 / 100 in placebo, p< NNT= 82 NEJM 2008;359 (21): Should We Use Niacin? Lowers LDL by 8% Lowers Lp(a ) by 20% Raise HDL-C cholesterol by 29% Side effects of niacin FLUSHING (about 1/3 have severe flushing, and 25% D/C because of it) (1) increased uric acid Slight effect on glucose 1) Clin Ther 2009; 31 (1): Statins Alone or With Niacin or Ezetimibe Open label, 12-week study of 292 patients who qualified for lipid lowering therapy Patients randomized to 4 arms, atorvastatin/niacin ER, Rosuvastatin/niacin ER, simvastatin/ezetimibe or rosuvastatin alone. All groups lowered LDL cholesterol by 50% or more, statin ER niacin combinations raised HDL cholesterol by 20%, where non niacin combinations raised HDL by 8%, p< % in simvastatin ezetimibe and rosuvastatin arms completed the study, only 75% in the niacin arms Atherosclerosis 2007;192: A 70 yo man presents for primary care. He has a history of CAD with an MI 2 years ago. His current medications include Atorvastatin, Aspirin, Isosrbide mononitrate, Omeprazole, Metoprolol, Folate, Vitamin E, Calcium, Multiple vitamin, Fish Oil. What do you most strongly recommend stopping in this patient? A) Aspirin B) Folate C) Vitamin E D) Calcium E) Multiple Vitamin Vitamin E and Statins Don t Mix Methods: Double blind trial of 160 patients with CAD, low HDL, normal LDL randomly assigned to simvastatin + niacin, antioxidents, simvastatin+ niacin +antioxidants, or placebo. Endpoints were arteriographic evidence of a change in coronary stenosis and occurance of 1 st cardiovascular event 6 6

7 Vitamin E and Statins Don t Mix The protective increase in HDL 2 with simvastatin plus niacin was attenuated by antioxidant use. Average stenosis increased by 3.9% with placebo, 1.8% with antioxidants,.7% with simvastatin/niacin/antioxidants and regressed by.4% with simvastatin-niacin. Cardiovascular events: 24% placebo, 21% antioxidants, 14% simvastatin/niacin antioxidants and 3% simvastatin/niacin NEJM 2001; 345: How to Use Niacin Rarely useful by itself (limited by flushing at higher doses) If you are going to use it by itself, best for patients with low HDL, normal LDL Very underused in combination with statins (can use lower doses of niacin and get good effect) Tricks to Using Niacin Use ER product Dose it at night! Give it with ASA Side Effects of Statins Rhabdomyolysis (rare) 3.4/100,000 py Hepatotoxicity (rare) Liver failure.1-.5/ 100,000 py Myalgias 10-15% Drugs That Increase Risk of Statin Toxicity Fibrates (Gemfibrozil >> Fenofibrate) Azole antifungals Amiodarone Erythromycin/Clarithromycin Protease inhibitors Verapamil/Diltiazem Niacin (do not use high doses) Approach To Statin-Related Muscle Symptoms Use lowest possible statin dose Use lower doses in Asians Discontinue medicine and report sudden onset of symptoms No need to monitor CK levels in asymptomatic patients(except in patients with drug interaction) If myalgias are severe, stop drug,let symptoms resolve, then start different statin In muscle cell toxicity studies pravastatin and rosuvastatin least toxic, simvastatin the most. 7 7

8 Some Important Drug Interactions A 49 yo woman with a recent history of breast cancer comes to clinic with worsening hot flashes. She is waking up several times at night with symptoms. Her breast cancer was diagnosed 18 months ago. She had 2 positive axillary lymph nodes. The cancer was ER+. She was placed on tamoxifen. What do you recommend for her hot flashes? A) Estrogen + Progesterone B) Estrogen C) Sertraline D) Paroxetine E) Citalopram SSRI s and Tamoxifen All women started on Tamoxifen over a 30 month period and continued for 2 years were studied (National Medco intergrated database) 1,298 women were identified. Divided into 2 groups, those who took a CYP2D6 inhibitor (353, 27%) and those who didn t (945,73%) Of those who took an SSRI (60%), those who took a potent inhibitor,213 (fluoxetine, sertraline,paroxetine) had a recurrence rate of 16% compared to those who took a less potent inhibitor, 137 (citalopram, escitalopram or fluvoxamine) 8.8% Aubert RE et al Increased risk of breast cancer recurrence in women taking tamoxifen and CYP2D6 inhibitors, ASCO annual meeting,may 2009 Hot Flashes in Women on Tamoxifen Avoid fluoxetine, sertraline and paroxetine (if you must use one of these, could switch tamoxifen to an aromatase inhibitor If you choose an SSRI, use citalopram, escitalopram or fluvoxamine Venlafaxine Gabapentin Clonidine Pharmacist calls to tell you that you are prescribing a triptan for a patient who is on an SSRI (citalopram 20 mg a day). She is on no other meds. What should you do? A) Switch to another migraine treatment B) Have patient not take citalopram for 24 hours after taking the triptan C) Cut the dose of triptan by 50 % D) Don t worry Triptans and SSRI s Concern for serotonergic syndrome Extremely unlikely if only a triptan + SSRI (especially at lower doses of SSRI) Beware of patients on multiple drugs that can trigger serotonergic syndrome ( tramadol, linezolid,meperidine, dextromethorphan, TCA, MAOI, buspirone, trazadone) 8 8

9 Pharmacist calls you to tell you that she did not fill the Tadalafil (10mg) prescription you wrote for your patient because he is on tamsulosin. What do you do? A) Switch Tamsulosin to Finaseride B) Switch Tamsulosin to Alfuzosin C) Switch Tadalafil to Sidenafil D) Ask that the prescription be filled Alpha blockers and Tadalafil.4 mg of tamsulosin was given for 7 days in healthy volunteers, then tadalafil 10mg,20 mg or placebo were given two hours after tamsulosin dose No significant difference in standing SBP with either dose of tadalafil and placebo, no one had a SBP < 85, no dizziness. J Urol 2004; 172: Managing Drug Interactions with PDE5 Inhibitors Nitrates Ok to give NTG > 4 hours after sildenafil use, 24 hours after vardenafil use and 48 hours after tadalafil use Alpha Blockers Ok to use in patients who are on stable alpha blocker therapy. For patients on doxazosin or terazosin, should not take within 4 hours of a dose to avoid potential drop in BP A 72 y.o. male S/P AVR replacement two years ago for aortic stenosis presents with wide spread bruising on his back/legs and some bruising on the back of both hands. His last INR was three weeks ago and was 3.0. He states he saw an M.D. six days ago for a cough and was put on a medication described as a white tablet. His chronic medications include: Coumadin 5 mg qd, Albuterol inhaler 2 puffs 4 times a day and Nortryptiline 25 mg qhs. What medication was he placed on? a) Amoxicillin b) Codeine c) Cefixime d) Azithromycin e) TMP/Sulfa Warfarin Interactions Decrease metabolism (increase PT) Most Severe Possible* TMP/Sulfa Quinolones Erythromycin Omeprazole Amiodarone Clarithromycin Propafenone Azithromycin Ketoconazole/fluconazole Itraconazole Metronidazole * Especially in elderly and polypharmacy 9 9

10 Antibiotics and Warfarin Retrospective cohort study 104 patients on stable warfarin therapy. Effect on INR of Terazocin (control), Azithromycin (32 patients), Levofloxacin (27) and TMP/Sulfa (16) Mean change in INR: Terazocin -.15, Azithromycin +.51, Levofloxacin +.85, TMP/Sulfa Percent patients having a INR > 4: Terazocin 5%, Azithromycin 31%, Levofloxacin 33%, TMP/Sulfa 69% JGIM 2005;20 (7);

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant

More information

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine

More information

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult

More information

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated

More information

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Placebo-Controlled Statin Trials Prevention Of CVD in Women MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

Hypertension Pharmacotherapy: A Practical Approach

Hypertension Pharmacotherapy: A Practical Approach Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.

More information

APPENDIX D: PHARMACOTYHERAPY EVIDENCE

APPENDIX D: PHARMACOTYHERAPY EVIDENCE Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991

More information

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic 1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Preventing and Treating High Blood Pressure

Preventing and Treating High Blood Pressure Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%

More information

Drug Interactions And Side Effects For 2017

Drug Interactions And Side Effects For 2017 Drug Interactions And Side Effects For 2017 Disclosure of Financial Relationships Douglas Paauw Has no relationships with any entity producing, marketing, re-selling, or distributing health care goods

More information

Lipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology

Lipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring

More information

No relevant financial relationships

No relevant financial relationships MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,

More information

Case 1. Case 2. What do you think about reducing or discontinuing some of the above now that his LVEF has normalized?

Case 1. Case 2. What do you think about reducing or discontinuing some of the above now that his LVEF has normalized? Case 1 A primary care colleague inquires what to do with a patient (HFrEF in NSR) who has a digoxin level of 2.8ng/ml. Level was obtained at 10am, patient takes all medications at one time upon arising

More information

Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation. Hot Off the Press and into Your Practice: The Last Year in Medical News

Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation. Hot Off the Press and into Your Practice: The Last Year in Medical News Hot Off the Press and into Your Practice: The Last Year in Medical News Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Moyer VA, et al. Ann Internal Med. 2014;160(5):330-338.

More information

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment

More information

Updates in Cardiovascular Recommendations for Diabetic Patients

Updates in Cardiovascular Recommendations for Diabetic Patients Updates in Cardiovascular Recommendations for Diabetic Patients Chris Tawwater, Pharm.D., BCPS Clinical Pharmacist, Abilene Regional Medical Center Assistant Professor, Adult Medicine Division Pharmacotherapy

More information

Jared Moore, MD, FACP

Jared Moore, MD, FACP Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner

More information

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Objectives Present patient case Review epidemiology/pathophysiology

More information

Update in Hypertension

Update in Hypertension Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded

More information

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals

More information

Diabetes Complications Guideline Based Screening, Management, and Referral

Diabetes Complications Guideline Based Screening, Management, and Referral Diabetes Complications Guideline Based Screening, Management, and Referral Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine Assistant Medical Director Altru Diabetes

More information

Modern Management of Hypertension: Where Do We Draw the Line?

Modern Management of Hypertension: Where Do We Draw the Line? Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

Difficult to Treat Hypertension

Difficult to Treat Hypertension Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic

More information

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology

More information

Modern Management of Hypertension

Modern Management of Hypertension Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence

More information

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured. Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.

More information

Management of Hypertension

Management of Hypertension Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal

More information

New Hypertension Guidelines. Kofi Osei, MD

New Hypertension Guidelines. Kofi Osei, MD New Hypertension Guidelines Kofi Osei, MD None Disclosures Objectives The new blood pressure definitions and cardiovascular risk The role to time and location in the diagnosis of hypertension Apply evidence-based

More information

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for

More information

How to Handle Statin Intolerance in the High Risk Patient

How to Handle Statin Intolerance in the High Risk Patient How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl

More information

Treating Hypertension in Individuals with Diabetes

Treating Hypertension in Individuals with Diabetes Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any

More information

Hypertension (JNC-8)

Hypertension (JNC-8) Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint

More information

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension

More information

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN 1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification

More information

Managing Hypertension in 2016

Managing Hypertension in 2016 Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

Hypertension 2015: Recent Evidence that Will Change Your Practice

Hypertension 2015: Recent Evidence that Will Change Your Practice Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School

More information

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient

More information

Treating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC

Treating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label

More information

Presenter Disclosure Information

Presenter Disclosure Information Presenter Disclosure Information 10:45 11:45 am Critical Caveats for Common Medications SPEAKER Genevieve L. Pagalilauan, MD The following relationships exist related to this presentation: Genevieve Pagalilauan,

More information

Statin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018

Statin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018 Statin Intolerance 2 nd Annual CV Course for Trainees and Early Career Physicians: Current Concepts in the Diagnosis and Management of Coronary Artery Disease Jason Evanchan DO, FACC April 20 th, 2018

More information

No relevant financial relationships

No relevant financial relationships MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu

More information

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure

More information

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015 Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor

More information

Pharmacologic Management of Hypertension

Pharmacologic Management of Hypertension Current Concepts In Management of Fernando Vega, MD Secondary - Definition Renovascular Disease (The kidney doesn t get impressed by blood pressure) Renovascular stenosis Renal artery stenosis Fibromuscular

More information

Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation. Hot Off the Press and into Your Practice: The Last Year in Medical News

Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation. Hot Off the Press and into Your Practice: The Last Year in Medical News Presenter Disclosure Information 1:45 3pm Hot Off the Press and Into Your Practice 2014 The following relationships exist related to this presentation: Michael J. Bloch, MD, FACP, FASH, receives consulting

More information

FEATURES OF THIS TALK

FEATURES OF THIS TALK FEATURES OF THIS TALK OUTPATIENT MANAGEMENT OF CAD- A PRIMARY CARE PERSPECTIVE Michael G. Shlipak, MD, MPH Professor of Medicine, Biostatistics, and Epidemiology Chief, General Internal Medicine Covers

More information

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered

More information

Management of High Blood Pressure in Adults

Management of High Blood Pressure in Adults Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management

More information

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the

More information

Conflicts of interest. What's the Skinny on the Lipid Guidelines? Key Differences. Are you applying the new ACC/AHA Lipid guidelines in your practice?

Conflicts of interest. What's the Skinny on the Lipid Guidelines? Key Differences. Are you applying the new ACC/AHA Lipid guidelines in your practice? Conflicts of interest What's the Skinny on the Lipid Guidelines? The presenter has no relevant conflicts of interest to disclose. Kathleen Vest, PharmD, CDE, BCACP At the end of this presentation, pharmacist

More information

STANDARD treatment algorithm mmHg

STANDARD treatment algorithm mmHg STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If

More information

Lipids & Hypertension Update

Lipids & Hypertension Update Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual

More information

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives

More information

What in the World is Functional Medicine?

What in the World is Functional Medicine? What in the World is Functional Medicine? An Introduction to a Systems Based Approach of Chronic Disease Meneah R Haworth, FNP-C Disclosure v I am a student of the Institute for Functional Medicine. They

More information

Hypertension in the very old. Objectives: Clinical Perspective

Hypertension in the very old. Objectives: Clinical Perspective Harvard Medical School Hypertension in the very old Ihab Hajjar, MD, MS, AGSF Associate Director, CV Research Lab Assistant Professor of Medicine, Harvard Medical School Objectives: Describe the clinical

More information

Chapter / Section / Drug

Chapter / Section / Drug 2 Cardiovascular System 2.1 Positive inotropic drugs Digoxin Digoxin specific antibody ( DigiFab ) 2.2 Diuretics 2.2.1 Thiazides and related diuretics Indapamide (1 st Line) Bendroflumethiazide Metolazone

More information

Topic: Chronic Heart Failure Cases for Monday s March 21th lecture.

Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. 1 Phar6122: CV section Date: 3/21/05 Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. Directions: This handout includes three chronic heart failure cases of increasing difficulty. In

More information

Pre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.

Pre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers. Pre- Drug Use % of Treated Patients on Medication 60 50 40 30 20 10 0 1978 Diuretics ß-Blockers ACE Inhibitors Year CCBs CCBs Beta Blockers Diuretics ACE Inhibitors 1980 1982 1984 1986 1988 1990 1992 IMS

More information

Hypertension Update 2009

Hypertension Update 2009 Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin

More information

Placebo-Controlled Statin Trials

Placebo-Controlled Statin Trials PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of

More information

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

4 th and Goal To Go How Low Should We Go? :

4 th and Goal To Go How Low Should We Go? : 4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose

More information

Hypertension, Hyperlipidemia and Obesity. Mi-CCSI

Hypertension, Hyperlipidemia and Obesity. Mi-CCSI Hypertension, Hyperlipidemia and Obesity Mi-CCSI Objectives Review the prevalence of hypertension, hyperlipidemia and obesity Correlation of the 3 conditions Discuss why it is important to treat these

More information

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity

More information

Have participants measure their blood pressure daily at a standard time for two weeks. Obtain BP values from participant (fax, call, , mail).

Have participants measure their blood pressure daily at a standard time for two weeks. Obtain BP values from participant (fax, call,  , mail). Blood Pressure Management and Control Protocol BP Management: A) BP goal: Achieve blood pressure values less than 130/80mmHg. B) Process: Have participants measure their blood pressure daily at a standard

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College

More information

Non-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016

Non-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016 Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4

More information

Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center

Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode

More information

Hypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy

Hypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic

More information

Current Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN

Current Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN Current Migraine Treatment Therapy Daniel Kassicieh, DO, FAAN Migraine a Disease Process Migraines are a chronic disease process similar to many other chronic medical conditions Migraine has a low mortality

More information

Lipid Panel Management Refresher Course for the Family Physician

Lipid Panel Management Refresher Course for the Family Physician Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new

More information

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic

More information

hypertension Head of prevention and control of CVD disease office Ministry of heath

hypertension Head of prevention and control of CVD disease office Ministry of heath hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension

More information

The State of Hypertension in NZ in 2010 personal view

The State of Hypertension in NZ in 2010 personal view The State of Hypertension in NZ in 2010 personal view Patient referred to medical clinic Dear Dr, Please see this man with resistant hypertension 50 year old European male Blood Pressure on current meds

More information

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977

More information

Preoperative Cardiac Evaluation:

Preoperative Cardiac Evaluation: Preoperative Cardiac Evaluation: The New Guidelines Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Disclosures No financial relationships with pharmaceutical

More information

Prof. Ramzy H. El Mawardy. Cairo Egypt 2009

Prof. Ramzy H. El Mawardy. Cairo Egypt 2009 Prof. Ramzy H. El Mawardy Ain Shams University Cairo Egypt 2009 Burden of HRN is increasing worldwide = 7 billion individuals. BP control is still poor = 60.70%. Global risk assessment is essential in

More information

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine

More information

Drug Interactions for the Emergency Physician. Lisa Thurgur

Drug Interactions for the Emergency Physician. Lisa Thurgur Drug Interactions for the Emergency Physician Lisa Thurgur Objectives Why we should care about drug-drug interactions Cases How can we avoid these interactions Short list of culprit drugs Drug-Drug Interaction

More information

Clinical Controversies in Perioperative Medicine

Clinical Controversies in Perioperative Medicine Clinical Controversies in Perioperative Medicine Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Cardiac Evaluation: New Guidelines A 70-y.o. man with progressive

More information

The Latest Generation of Clinical

The Latest Generation of Clinical The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform

More information

Heart Failure Clinician Guide JANUARY 2018

Heart Failure Clinician Guide JANUARY 2018 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.

More information

Lipids What s new? Meera Jain, MD Providence Portland Medical Center

Lipids What s new? Meera Jain, MD Providence Portland Medical Center Lipids 2016- What s new? Meera Jain, MD Providence Portland Medical Center 1 Can I trust the ASCVD risk calculator? Do harms outweigh benefits in primary prevention? Is there anything besides a statin?

More information

Clinical Controversies in Perioperative Medicine

Clinical Controversies in Perioperative Medicine Update on Perioperative Medicine Clinical Controversies in Perioperative Medicine Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Cardiac Medications & Perioperative

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

CARDIAC REHABILITATION PROGRAMME:- MEDICATION

CARDIAC REHABILITATION PROGRAMME:- MEDICATION CARDIAC REHABILITATION PROGRAMME:- MEDICATION AIM OF THIS SESSION Understand the reasons for taking your medications, Discuss the common side effects associated with these medications - knowing when to

More information